Mahmoud El-Yassir, MD
Ophthalmology · Jackson, MINPI 1245590868
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,734 of the $8,830 with a category attached, or 64.9%. Alcon accounts for 61.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $4,372 and has fallen 56.4% since, to $1,905 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 230 payments — averaging $38.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$5K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$299
- Johnson & Johnson Surgical Vision, Inc.$275
- Sight Sciences, Inc.$213
- Novartis$180
- plus $866 from 17 others
What the payments were for
- Travel & lodging$3,06135%
- Food & beverage$5,73465%
- Entertainment$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 67 | $5,467 |
| AbbVie(2 entities) | 64 | $1,530 |
| Sun Pharmaceutical Industries Inc. | 23 | $299 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $275 |
| Sight Sciences, Inc. | 11 | $213 |
| Novartis | 9 | $180 |
| Biotissue Holdings Inc. | 5 | $152 |
| Bausch & Lomb Americas Inc. | 6 | $115 |
| NEW World Medical,inc. | 9 | $103 |
| Amgen(2 entities) | 4 | $69 |
| Dompe US, Inc. | 3 | $60 |
| Glaukos Corporation | 2 | $55 |
| Beaver-visitec International, Inc. | 2 | $47 |
| Thea Pharma Inc. | 2 | $46 |
| Optos, Inc. | 1 | $36 |
| Ivantis, Inc | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $23 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Rxsight Inc | 1 | $18 |
| Eyepoint US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,883
- LenSx$1,740
- ARGOS$1,615
- Centurion$1,615
- Hydrus Microstent$395
- AcrySof IQ PanOptix UV IOL$122
- XEN GLAUCOMA TREATMENT SYSTEM$111
How this compares
$8,830 in reported general payments places this provider in the 90th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 342 | $198,611 |
| RestasisCyclosporine | 79 | $112,069 |
| CombiganBrimonidine Tartrate/Timolol | 80 | $42,865 |
| VyzultaLatanoprostene Bunod | 73 | $29,684 |
| Cyclosporine | 48 | $21,601 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 64 | $21,039 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $17,684 |
| Alphagan PBrimonidine Tartrate | 45 | $16,280 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 64 | $12,502 |
| Brimonidine Tartrate | 138 | $11,524 |
| Latanoprost | 486 | $10,606 |
| Prednisolone Acetate | 169 | $10,330 |
| Brinzolamide | 37 | $8,979 |
| TafluprostTafluprost/Pf | 21 | $5,491 |
| Timolol Maleate | 122 | $5,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,530 | $369,825546 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $115 | $29,68473 claims |
| AlconSimbrinza | $5,467 | $21,03964 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $21 | $7,88031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Jackson
- Kevin LaveryJackson$9K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.